The availability of immunohistochemical markers to identify loss of INI1 expression in rhabdoid tumors and the 2014 international histologic consensus classification of pediatric liver tumors improved the classification of pediatric liver tumors at diagnosis resulting in more accurate classification and fewer tumors erroneously diagnosed as HB, particularly in patients with AFP less than 100 ng/mL [2]. This evidence concerns the gene SMARCB1 and hemoglobin measurement.